PMS2 and neoplasm: In the IHC method, loss of MMR expression is determined by lack of immunohistochemical staining of MMR proteins (MLH1 MSH2, MSH6, PMS2) in the nuclei of tumour cells.5 Because it detects the absence of specific MMR proteins, IHC can also inform subsequent genetic testing for germline mutations.